Showing results (11-20 of 333) with videos related to
Sort By:
Pageof 34
Expert Opinion on Pharmacotherapy|November 8, 2013
Fasiglifam as a new potential treatment option for patients with type 2 diabetesKohei KakuJournal of Diabetes Investigation|September 1, 2019
New concept of the glucagon-like peptide-1 signaling pathway on pancreatic insulin secretionKohei KakuExpert Opinion on Drug Safety|August 23, 2017
Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patientsKohei KakuExpert Opinion on Pharmacotherapy|November 3, 2015
First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitusKohei KakuCurrent Medical Research and Opinion|March 25, 2009
Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trialKohei KakuEndocrine Journal|June 16, 2015
Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytesFuminori Tatsumi, Hideaki Kaneto, Mitsuru Hashiramoto, et al.Journal of Diabetes Investigation|May 17, 2016
Controversy about the relationship between sulfonylurea use and cardiovascular events and mortalityMasashi Shimoda, Kohei KakuNihon Rinsho. Japanese Journal of Clinical Medicine|February 18, 2010
[A target of PPARgamma agonist: diabetes mellitus]Mitsuru Hashiramoto, Kohei KakuExpert Opinion on Pharmacotherapy|March 26, 2026
Persistence of fixed-dose combinations including dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes in Japan: analysis using a claims databaseKohei Kaku, Yusuke NaitoNihon Rinsho. Japanese Journal of Clinical Medicine|May 21, 2011
[Alogliptin]Akihito Tanabe, Kohei KakuPageof 34